Baron Global Advantage Fund advanced during the fourth quarter of 2024, outperforming its benchmark, the MSCI ACWI Index.

With the goal of informing clinician practice, a new study explores the harms and benefits of continuing and of discontinuing the long-term prescription of opioid medicines to adults with chronic pain ...